Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HBB | P68871 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1436456 | 0.81 | FDPS (0.39) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL1892112 | 0.81 | CYP1A2 (0.44) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL2894577 | 0.75 | FDPS (0.40) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL28215610 | 0.74 | LTA4H (0.38) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL5495655 | 0.72 | FDPS (0.42) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL13281305 | 0.72 | FDPS (0.41) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL27763737 | 0.71 | FDPS (0.41) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL1398869 | 0.71 | FDPS (0.41) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL5440115 | 0.70 | LTA4H (0.50) | FDPSLTA4HHDAC1HDAC6ALDH1A1 | |
| SCHEMBL5756889 | 0.69 | FDPS (0.35) | FDPSLTA4HHDAC1HDAC6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180346913-A1 | CHEMICALLY MODIFIED MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE | BANK OF AMERICA, N.A. | 2018-12-06 | — | — | US | disclosed |
| US-9994853-B2 | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference | SIRNA THERAPEUTICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20160272975-A1 | CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE | SIRNA THERAPEUTICS INC (US) | 2016-09-22 | — | — | US | disclosed |
| EP-1931781-B1 | CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE | SIRNA THERAPEUTICS INC (US) | 2016-07-27 | — | — | EP | disclosed |
| US-20160152973-A1 | CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID MOLECULES THAT MEDIATE RNA INTERFERENCE | BANK OF AMERICA, N.A. | 2016-06-02 | — | — | US | disclosed |
| US-8258288-B2 | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110313024-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | MERCK SHARP & DOHME CORP. | 2011-12-22 | — | — | US | disclosed |
| US-20110288154-A1 | RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA) | MERCK & CO., INC. | 2011-11-24 | — | — | US | disclosed |
| EP-2370578-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF EPITHELIAL SODIUM CHANNEL (ENaC) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | Merck Sharp&Dohme Corp. (US) | 2011-10-05 | — | — | EP | disclosed |
| US-7935812-B2 | A composition comprising two double stranded nucleic acid molecules ; nucleic acids with a pyrimidine modification | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20050287128-A1 | Transforming growth factor; moderating gene expression; reducing time for hematopoiety after drug or radiation therapy | SIRNA THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050282188-A1 | Small nucleic acid molecules with reduced or attenuated immunostimulatory properties; improved toxicologic | SIRNA THERAPEUTICS, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| US-20050277133-A1 | Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy | SIRNA THERAPEUTICS, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050261219-A1 | Moderator of gene expression; small nucleic acids; anticancer agents; antiinflammatory agents; respiratory system disorders; autoimmune disease; cardiovascular disorders ; central nervous system disorders | SIRNA THERAPEUTICS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050260620-A1 | Hearing loss, deafness, tinnitus, motion and balance disorders, cancer and proliferative diseases | SIRNA THERAPEUTICS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005105995-A2 | RNA INTERFERENCE MEDIATED TREATMENT OF POLYGLUTAMINE (POLYQ) REPEAT EXPANSION DISEASES USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| US-20050233998-A1 | useful in modulating vascular endothelial growth factor (VEGF) and/or vascular endothelial growth factor receptor (e.g., VEGFR) gene expression; use in therapeutic, diagnostic, target validation, and genomic discovery | SIRNA THERAPEUTICS, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050222066-A1 | useful in modulating vascular endothelial growth factor (VEGF) and/or vascular endothelial growth factor receptor (e.g., VEGFR) gene expression; asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis | SIRNA THERAPEUTICS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| US-20050196781-A1 | Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy | SIRNA THERAPEUTICS, INC. (US) | 2005-09-08 | — | — | US | disclosed |
| WO-2005028649-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050233998-A1 | useful in modulating vascular endothelial growth factor (VEGF) and/or vascular endothelial growth factor receptor (e.g., VEGFR) gene expression; use in therapeutic, diagnostic, target validation, and genomic discovery | KDR, VEGFA, FLT1 | FDPS 3623/4885LTA4H 4345/4885HDAC1 1274/4885 |
| US-20050260620-A1 | Hearing loss, deafness, tinnitus, motion and balance disorders, cancer and proliferative diseases | RB1, RBBP5, BCCIP | FDPS 3867/4885LTA4H 3461/4885HDAC1 440/4885 |
| US-20110313024-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 (PCSK9) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) | PCSK9, PCSK6, PCSK7 | FDPS 623/4885LTA4H 2139/4885HDAC1 529/4885 |
| US-20050261219-A1 | Moderator of gene expression; small nucleic acids; anticancer agents; antiinflammatory agents; respiratory system disorders; autoimmune disease; cardiovascular disorders ; central nervous system disorders | IL23R, IL15RA, IL2RA | FDPS 4714/4885LTA4H 3052/4885HDAC1 414/4885 |
| US-20050287128-A1 | Transforming growth factor; moderating gene expression; reducing time for hematopoiety after drug or radiation therapy | TGFBR2, TGFBR1, INHA | FDPS 3064/4885LTA4H 3192/4885HDAC1 1019/4885 |
| US-20050222066-A1 | useful in modulating vascular endothelial growth factor (VEGF) and/or vascular endothelial growth factor receptor (e.g., VEGFR) gene expression; asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis | KDR, VEGFA, FLT1 | FDPS 4166/4885LTA4H 1056/4885HDAC1 767/4885 |
| US-20050196781-A1 | Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy | STAT3, POLI, SNRPE | FDPS 3092/4885LTA4H 4630/4885HDAC1 218/4885 |
| US-20110288154-A1 | RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA) | SCNN1A, SCNN1B, SCNN1G | FDPS 3878/4885LTA4H 3723/4885HDAC1 401/4885 |
| US-20050277133-A1 | Study and interfererance, diagnosis and treatment of polyglutamine using short interfering nucleic acid for treatment of dementia or siezures or muscular dystrophy | SNRPE, HNRNPA1, SNRPA1 | FDPS 2701/4885LTA4H 4579/4885HDAC1 261/4885 |
| US-20050282188-A1 | Small nucleic acid molecules with reduced or attenuated immunostimulatory properties; improved toxicologic | EIF2AK2, STING1, AGO2 | FDPS 2789/4885LTA4H 4121/4885HDAC1 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.